• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Hospira

Hospira

Hospira Inc HSP 3 Star

Last Price$87.82Day Change (%)0.10%
Open Price$87.74Day Change ($)0.09
Day Range87.72–87.8452-Week Range42.01–88.09

As of Tue 3/31/2015 3:31:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Hospira's INFLECTRA™ (Infliximab) Now Available in Canada

    Hospira's INFLECTRA™ (Infliximab) Now Available in Canada

  2. UPDATE: These are the top-performing S&P 500 stocks of 2015

    UPDATE: These are the top-performing S&P 500 stocks of 2015

  3. UPDATE: These are the top-performing S&P 500 stocks of 2015

    UPDATE: These are the top-performing S&P 500 stocks of 2015

  4. UPDATE: These are the top-performing S&P 500 stocks of 2015

    UPDATE: These are the top-performing S&P 500 stocks of 2015

  5. Hospira Statement on FDA Approval of the First Biosimilar in the United States

    Hospira Statement on FDA Approval of the First Biosimilar in the United States

  6. Research and Markets: PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis to 2023

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis to 2023

  7. Research and Markets: PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023: France, Germany, Italy, Spain, UK

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023: France, Germany, Italy, Spain, UK

  8. Research and Markets: PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

  9. Research and Markets: Global HER-2 Positive Breast Cancer Market 2015-2019 with Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Sanofi Dominating

    Research and Markets: Global HER-2 Positive Breast Cancer Market 2015-2019 with Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Sanofi Dominating

  10. Research and Markets: PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.